Annual report pursuant to Section 13 and 15(d)

Commitments and Contingencies (Tables)

v2.4.0.8
Commitments and Contingencies (Tables)
12 Months Ended
Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]  
Schedule Of Principal Cash Obligations and Commitments [Table Text Block]
The following table sets forth the Company’s principal cash obligations and commitments for the next five fiscal years as of December 31, 2013 aggregating $ 2,119,565, of which $213,000 is included in current liabilities in the consolidated balance sheet at December 31, 2013.
 
 
 
 
 
Payments Due By Year
 
 
 
Total
 
2014
 
2015
 
2016
 
2017
 
2018
 
Research and development contracts
 
$
40,385
 
$
40,385
 
$
—
 
$
—
 
$
—
 
$
—
 
Theradex work order agreement
 
 
1,746,463
 
 
1,346,463
 
 
400,000
 
 
—
 
 
—
 
 
—
 
Patent license agreement
 
 
150,000
 
 
30,000
 
 
30,000
 
 
30,000
 
 
30,000
 
 
30,000
 
Consulting agreement
 
 
16,000
 
 
16,000
 
 
—
 
 
—
 
 
—
 
 
—
 
Liquidated damages payable under registration rights agreement
 
 
74,000
 
 
74,000
 
 
—
 
 
—
 
 
—
 
 
—
 
Due to stockholder
 
 
92,717
 
 
92,717
 
 
—
 
 
—
 
 
—
 
 
—
 
Total
 
$
2,119,565
 
$
1,599,565
 
$
430,000
 
$
30,000
 
$
30,000
 
$
30,000